MOBIDIAG
Mobidiag Ltd, a Finnish molecular diagnostics company, today announced an agreement with Biomedica Medizinprodukte GmbH & Co KG, provider of a large panel of medical products for health professionals, medical scientists, and research laboratories, for the distribution of the Amplidiag® product line. Under this new agreement Biomedica Medizinprodukte becomes the exclusive distributor of Amplidiag®, in vitro diagnostics for gastrointestinal infections, in Central and Eastern Europe (Austria, Bosnia & Herzegovina, Bulgaria, Croatia, Czech Republic, Hungary, Macedonia, Poland, Romania, Serbia, Slovakia, Slovenia).
“Since Mobidiag’s inception, we have been focusing our activity towards Nordic region and France mainly. Three months ago, we have started developing our distribution network by extending our European coverage to Spain and Benelux. We are very pleased today to expand Amplidiag accessibility to Central and Eastern Europe with the support of our partner, Biomedica Medizinprodukte” said Tuomas Tenkanen, CEO at Mobidiag.
“Rapid and reliable detection of gastrointestinal infections is crucial for preventing transmission of contagious pathogens. With Amplidiag products, we will ensure the distribution of innovative, quality products that will significantly impact infection control” said Dr. Michaela Weblacher, Executive Vice President at Biomedica.
The distribution agreement is effective immediately and covers all Amplidiag® products (Amplidiag® H. pylori+ClariR, Amplidiag® Stool Parasites, Amplidiag® CarbaR+VRE, Amplidiag® C. difficile+027, Amplidiag® Bacterial GE, Amplidiag® Easy and upcoming Amplidiag® Viral GE).
About Amplidiag®
Amplidiag® are innovative multiplex tests
for the detection of gastrointestinal infections. They allow to screen
simultaneously panels of the most relevant gastrointestinal pathogens.
Based on well-established real-time PCR technology, they ensure optimal
performance, suitability for high-volume screening use and
cost-effectiveness in mid-sized to large laboratory settings.
About Mobidiag
Established in 2000, Mobidiag develops
innovative solutions to advance the diagnosis of infectious diseases and
serves the European clinical diagnostics market since 2008. Mobidiag is
headquartered in Espoo, Finland, with a subsidiary in Paris, France.
In addition to Amplidiag® assays, Mobidiag is able to address both high
volume and on demand testing with the new Amplidiag® Easy platform,
bringing the Amplidiag® suite further by automating the workflow from
sample to results, and the upcoming Novodiag® platform & associated
panels for a fully automated solution and suitable for smaller volumes
and labs.
Visit www.mobidiag.com
for more information.
About Biomedica Medizinprodukte GmbH & Co KG
With 13
offices in Central and Eastern Europe (CEE) and a team of more than 250
professionals, Biomedica is a leading distributor of medical devices,
in-vitro diagnostics, products for life sciences, Biomedica Immunoassays
and Clinical IT. With its headquarter in Vienna, Austria, Biomedica is
dedicated to strive for excellence, i.e. state-of-the-art products,
uncompromising professionalism in customer support and the best possible
service, in order to meet all customer demands at the highest level.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160904005004/en/
Contact:
Mobidiag Ltd.
Anne Aittakorpi, +358 10 5050 770
info@mobidiag.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ANTOGNOLLA25.4.2024 16:40:29 CEST | Press release
Antognolla at International Hospitality Investment Forum: Growing Interest in the Italian Market from Hotel Operators and Investors
CA-LASERFICHE25.4.2024 16:31:29 CEST | Press release
Digital Transformation’s Next Era: Generative AI and Laserfiche 12 at 2024 Empower Conference
ALPHA-BLUE-OCEAN25.4.2024 16:01:28 CEST | Press release
Alpha Blue Ocean Group and Europlasma, Expert in Depollution Solutions, Announce the Signing of a New €30 Million Financing Agreement
CT-INTERACTIVE-BROKERS25.4.2024 16:01:28 CEST | Press release
Interactive Brokers Announces Extended Trading Hours for US Treasury Bonds
VT-CANNATROL25.4.2024 14:04:26 CEST | Press release
Cannatrol, Creators of Breakthrough Postharvest Cannabis Technology, Receive Two European Patent Approvals
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom